
Takeda Pharmaceutical Company Limited: shareholders and insiders
Price
$21.41
November 19, 2026
What Ploutos Investor adds for Takeda Pharmaceutical
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from FY2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Jul 1, 2026 to Nov 5, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$15M
13 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan16%
- The rest84%
- Nov 4, 2026Giles Richard PlatfordPresident, IBUKind
- Nov 2, 2026Teresa Marie BitettiPresident, OBUKind
- Sep 14, 2026Lauren Rusckowski DupreyChief Transformation OfficerKind
- Sep 2, 2026Andrew Stewart PlumpPresident, R&DKind10b5-1
- Aug 19, 2026Andrew Stewart PlumpPresident, R&DKind10b5-1
- Aug 18, 2026Nicola Deidre Petal GreenwayChief Human Resources OfficerKind
- Aug 11, 2026Elaine Mary ShannonPres., Global Supply & QualityKind
- Aug 10, 2026Awny Samaan Botros FarajallahChief Medical OfficerKind
- Aug 10, 2026Ramy Riad Ahmed IbrahimPresident, PDT BUKind
- Aug 10, 2026Rhonda Janice PachecoPresident, U.S. Business UnitKind
- Aug 10, 2026Lauren Rusckowski DupreyChief Transformation OfficerKind
- Aug 10, 2026Andrew Stewart PlumpPresident, R&DKind
- Aug 10, 2026Agosti Marcello PignagnoliHead, Strat. & Port. DevKind
- Aug 10, 2026Teresa Marie BitettiPresident, OBUKind
- Aug 10, 2026Elaine Mary ShannonPres., Global Supply & QualityKind
- Aug 10, 2026Gabriele RicciChief Data & Tech. OfficerKind
- Aug 10, 2026Nicola Deidre Petal GreenwayChief Human Resources OfficerKind
- Aug 10, 2026Julie So-Young KimPresident and CEOKind
- Aug 10, 2026Giles Richard PlatfordPresident, IBUKind
- Aug 10, 2026Natalie Anne Marie FurneyGlobal General CounselKind
- Aug 10, 2026Nicola Deidre Petal GreenwayChief Human Resources OfficerKind
- Aug 10, 2026Nicola Deidre Petal GreenwayChief Human Resources OfficerKind
- Jul 1, 2026Steven GillisDirectorKind
- Jul 1, 2026John MaraganoreDirectorKind
- Jul 1, 2026Kimberly A. ReedDirectorKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | Giles Richard PlatfordPresident, IBU | 55.6K | $20.90 | $1.2M | Form 4 | |
| Nov 2, 2026 | Teresa Marie BitettiPresident, OBU | 46.6K | $20.89 | $973.7K | Form 4 | |
| Sep 14, 2026 | Lauren Rusckowski DupreyChief Transformation Officer | 34.5K | $18.54 | $640.3K | Form 4 | |
| Sep 2, 2026 | Andrew Stewart PlumpPresident, R&D | 10b5-1 | 116.2K | $18.49 | $2.1M | Form 4 |
| Aug 19, 2026 | Andrew Stewart PlumpPresident, R&D | 10b5-1 | 19.7K | $18.49 | $363.3K | Form 4 |
| Aug 18, 2026 | Nicola Deidre Petal GreenwayChief Human Resources Officer | 13.0K | $18.11 | $235.1K | Form 4 | |
| Aug 11, 2026 | Elaine Mary ShannonPres., Global Supply & Quality | 20.4K | $17.55 | $357.4K | Form 4 | |
| Aug 10, 2026 | Awny Samaan Botros FarajallahChief Medical Officer | 14.0K | $17.10 | $239.5K | Form 4 | |
| Aug 10, 2026 | Ramy Riad Ahmed IbrahimPresident, PDT BU | 7,277 | $17.10 | $124.4K | Form 4 | |
| Aug 10, 2026 | Rhonda Janice PachecoPresident, U.S. Business Unit | 16.9K | $17.10 | $289.0K | Form 4 | |
| Aug 10, 2026 | Lauren Rusckowski DupreyChief Transformation Officer | 47.6K | $17.10 | $813.7K | Form 4 | |
| Aug 10, 2026 | Andrew Stewart PlumpPresident, R&D | 165.4K | $17.10 | $2.8M | Form 4 | |
| Aug 10, 2026 | Agosti Marcello PignagnoliHead, Strat. & Port. Dev | 23.0K | $17.10 | $392.6K | Form 4 | |
| Aug 10, 2026 | Teresa Marie BitettiPresident, OBU | 50.0K | $17.10 | $855.2K | Form 4 | |
| Aug 10, 2026 | Elaine Mary ShannonPres., Global Supply & Quality | 3,978 | $17.10 | $68.0K | Form 4 | |
| Aug 10, 2026 | Gabriele RicciChief Data & Tech. Officer | 25.1K | $17.10 | $429.0K | Form 4 | |
| Aug 10, 2026 | Nicola Deidre Petal GreenwayChief Human Resources Officer | 6,774 | $17.10 | $115.8K | Form 4 | |
| Aug 10, 2026 | Julie So-Young KimPresident and CEO | 89.1K | $17.10 | $1.5M | Form 4 | |
| Aug 10, 2026 | Giles Richard PlatfordPresident, IBU | 31.1K | $17.10 | $531.5K | Form 4 | |
| Aug 10, 2026 | Natalie Anne Marie FurneyGlobal General Counsel | 30.9K | $17.10 | $527.8K | Form 4 | |
| Aug 10, 2026 | Nicola Deidre Petal GreenwayChief Human Resources Officer | 975 | $17.50 | $17.1K | Form 4 | |
| Aug 10, 2026 | Nicola Deidre Petal GreenwayChief Human Resources Officer | 33.6K | $17.51 | $588.7K | Form 4 | |
| Jul 1, 2026 | Steven GillisDirector | 3,800 | – | – | Form 4 | |
| Jul 1, 2026 | John MaraganoreDirector | 3,800 | – | – | Form 4 | |
| Jul 1, 2026 | Kimberly A. ReedDirector | 3,800 | – | – | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
No filing over 5%
Since Dec 18, 2024 nobody has filed a Schedule 13D or 13G for Takeda Pharmaceutical shares.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter-11%
- D.E. ShawIn the quarter+53%
- Millennium Mgmt (Englander)In the quarter+27%
- Point72 (Cohen)In the quarter+445%
- Citadel Advisors (Griffin)In the quarter+375%
- AQR CapitalIn the quarter+1.4%
- Bridgewater (Dalio)In the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 2.29M | -11% | $42M | 0.06% |
| D.E. Shaw | 3.14M | +53% | $57M | 0.04% |
| Millennium Mgmt (Englander) | 1.33M | +27% | $24M | 0.02% |
| Point72 (Cohen) | 423.4K | +445% | $7.7M | 0.01% |
| Citadel Advisors (Griffin) | 798.1K | +375% | $15M | 0.01% |
| AQR Capital | 1.55M | +1.4% | $28M | 0.01% |
| Bridgewater (Dalio) | 21.3K | $400.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short sales in daily trading
How much of the shares that changed hands were short sales, in the off-exchange trades brokers report each day.
In the last 14 sessions, 46.4% of the shares in the reported trades were short sales, against 33.9% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 46.4%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 33.9%
- Change
- +12.5 pts
- Short sales a dayon average, of 1.44M shares
- 666.3K
- More than atof 3,666 US-listed companies, same days
- 36%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 30.9%
- Oct 14, 2026: Short sales 37.4%
- Oct 15, 2026: Short sales 25.9%
- Oct 16, 2026: Short sales 26%
- Oct 19, 2026: Short sales 33.8%
- Oct 20, 2026: Short sales 29.5%
- Oct 21, 2026: Short sales 26.4%
- Oct 22, 2026: Short sales 25.5%
- Oct 23, 2026: Short sales 30%
- Oct 26, 2026: Short sales 36%
- Oct 27, 2026: Short sales 36.3%
- Oct 28, 2026: Short sales 38.8%
- Oct 29, 2026: Short sales 42.4%
- Oct 30, 2026: Short sales 48.5%
- Nov 2, 2026: Short sales 37.8%
- Nov 3, 2026: Short sales 44%
- Nov 4, 2026: Short sales 47.1%
- Nov 5, 2026: Short sales 51.2%
- Nov 6, 2026: Short sales 52.2%
- Nov 9, 2026: Short sales 43.8%
- Nov 10, 2026: Short sales 45.6%
- Nov 11, 2026: Short sales 33.5%
- Nov 12, 2026: Short sales 37.7%
- Nov 13, 2026: Short sales 59.9%
- Nov 16, 2026: Short sales 53.9%
- Nov 17, 2026: Short sales 44%
- Nov 18, 2026: Short sales 45.5%
- Nov 19, 2026: Short sales 48.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half. Shares held short, which are published twice a month, are not included here.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Andrew Stewart PlumpPresident, R&DDirectly912.0K
- Julie So-Young KimPresident and CEODirectly391.5K
- Giles Richard PlatfordPresident, IBUDirectly270.3K
- Teresa Marie BitettiPresident, OBUDirectly214.5K
- Natalie Anne Marie FurneyGlobal General CounselDirectly204.3K
- Lauren Rusckowski DupreyChief Transformation OfficerDirectly191.5K
- Rhonda Janice PachecoPresident, U.S. Business UnitDirectly182.5K
- Agosti Marcello PignagnoliHead, Strat. & Port. DevDirectly177.0K
- Gabriele RicciChief Data & Tech. OfficerDirectly171.7K
- Awny Samaan Botros FarajallahChief Medical OfficerDirectly116.2K
- Ramy Riad Ahmed IbrahimPresident, PDT BUDirectly102.6K
- Milano FurutaChief Financial OfficerDirectly70.2K
- Elaine Mary ShannonPres., Global Supply & QualityDirectly63.3K
- Nicola Deidre Petal GreenwayChief Human Resources OfficerDirectly40.0K
- Steven GillisDirectorDirectly22.1K
- Jennifer Marie SmoterChief Comm. & Gov. OfficerDirectly18.8K
- Kimberly A. ReedDirectorDirectly15.2K
- Masami IijimaDirectorDirectly14.6K
- John MaraganoreDirectorDirectly13.8K
- Miki TsusakaDirectorDirectly8,200
- Bruce D BroussardDirectorDirectly4,595
- Asuka MiyabashiraPresident, Japan Pharma B.U.Directly4,500
- Paulus StoffelsDirectorDirectly3,800
- Koichiro KimuraDirectorDirectly1,800
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Andrew Stewart PlumpPresident, R&D | 912.0K | – | Sep 2, 2026 | Form 4 |
| Julie So-Young KimPresident and CEO | 391.5K | – | Aug 10, 2026 | Form 4 |
| Giles Richard PlatfordPresident, IBU | 270.3K | – | Nov 4, 2026 | Form 4 |
| Teresa Marie BitettiPresident, OBU | 214.5K | – | Nov 2, 2026 | Form 4 |
| Natalie Anne Marie FurneyGlobal General Counsel | 204.3K | – | Aug 10, 2026 | Form 4 |
| Lauren Rusckowski DupreyChief Transformation Officer | 191.5K | – | Sep 14, 2026 | Form 4 |
| Rhonda Janice PachecoPresident, U.S. Business Unit | 182.5K | – | Aug 10, 2026 | Form 4 |
| Agosti Marcello PignagnoliHead, Strat. & Port. Dev | 177.0K | – | Aug 10, 2026 | Form 4 |
| Gabriele RicciChief Data & Tech. Officer | 171.7K | – | Aug 10, 2026 | Form 4 |
| Awny Samaan Botros FarajallahChief Medical Officer | 116.2K | – | Aug 10, 2026 | Form 4 |
| Ramy Riad Ahmed IbrahimPresident, PDT BU | 102.6K | – | Aug 10, 2026 | Form 4 |
| Milano FurutaChief Financial Officer | 70.2K | – | Jul 1, 2026 | Form 4 |
| Elaine Mary ShannonPres., Global Supply & Quality | 63.3K | – | Aug 11, 2026 | Form 4 |
| Nicola Deidre Petal GreenwayChief Human Resources Officer | 40.0K | – | Aug 18, 2026 | Form 4 |
| Steven GillisDirector | 22.1K | – | Jul 1, 2026 | Form 4 |
| Jennifer Marie SmoterChief Comm. & Gov. Officer | 18.8K | – | Jul 1, 2026 | Form 4 |
| Kimberly A. ReedDirector | 15.2K | – | Jul 1, 2026 | Form 4 |
| Masami IijimaDirector | 14.6K | – | Jul 1, 2026 | Form 4 |
| John MaraganoreDirector | 13.8K | – | Jul 1, 2026 | Form 4 |
| Miki TsusakaDirector | 8,200 | – | Jul 1, 2026 | Form 4 |
| Bruce D BroussardDirector | 4,595 | – | Jul 1, 2026 | Form 4 |
| Asuka MiyabashiraPresident, Japan Pharma B.U. | 4,500 | – | Jul 1, 2026 | Form 4 |
| Paulus StoffelsDirector | 3,800 | – | Jul 1, 2026 | Form 4 |
| Koichiro KimuraDirector | 1,800 | – | Jul 1, 2026 | Form 4 |
A lower bound: it counts only the 24 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- PPHVanEck Pharmaceutical ETFWeight in the fund2.87%
- DXJWisdomTree Japan Hedged Equity FundWeight in the fund1.65%
- EFAViShares MSCI EAFE Min Vol Factor ETFWeight in the fund1.41%
- EWJiShares MSCI Japan ETFWeight in the fund1.09%
- BBJPJPMorgan BetaBuilders Japan ETFWeight in the fund0.99%
- FLJPFranklin FTSE Japan ETFWeight in the fund0.80%
- IXJiShares Global Healthcare ETFWeight in the fund0.66%
- DFIVDimensional International Value ETFWeight in the fund0.58%
- JIREJPMorgan International Research Enhanced Equity ETFWeight in the fund0.49%
- VPLVanguard Pacific Stock Index FundWeight in the fund0.45%
35 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 330
- Q4 2025: Managers 351
- Q1 2026: Managers 362
- Q2 2026: Managers 376
Institutional investors by quarter
The fund managers holding TAK, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 376 managers held 104M shares, worth $1.7B. During the quarter 67 opened a position, 53 closed one, 142 added and 100 trimmed.
The largest holders, Q2 2026
- Capital Research Global InvestorsIn the quarter+1.0%
- FMRIn the quarter+35%
- Morgan StanleyIn the quarter+8.1%
- Adage Capital Partners GpIn the quarter-5.8%
- Goldman Sachs GroupIn the quarter-8.8%
- Brandes Investment PartnersIn the quarter+2.5%
- Arrowstreet Capital, Limited PartnershipIn the quarter+20%
- BlackRockIn the quarter+16%
- Renaissance TechnologiesIn the quarter-14%
- Qube Research & TechnologiesIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Capital Research Global Investors | 19.30M | +1.0% | $309M |
| FMR | 9.60M | +35% | $154M |
| Morgan Stanley | 6.99M | +8.1% | $112M |
| Adage Capital Partners Gp | 6.05M | -5.8% | $97M |
| Goldman Sachs Group | 5.13M | -8.8% | $82M |
| Brandes Investment Partners | 4.54M | +2.5% | $73M |
| Arrowstreet Capital, Limited Partnership | 3.73M | +20% | $60M |
| BlackRock | 3.69M | +16% | $59M |
| Renaissance Technologies | 2.57M | -14% | $41M |
| Qube Research & Technologies | 2.21M | $35M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Takeda Pharmaceutical's filings show?
Who buys and sells is one part of Takeda Pharmaceutical's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have TAK's insiders bought or sold?
From Jul 6, 2026 to Nov 5, 2026 Takeda Pharmaceutical's insiders bought 0 and sold $15M of shares on the market. 16% of the sales were under set 10b5-1 plans.
Which well-known managers hold TAK?
7 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $57M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.